The first head-to-head trial comparing ustekinumab and adalimumab has found the two drugs are similarly safe and effective in patients with moderate to severe Crohn’s disease.
The results, along with the lack of immunogenicity and the convenience of administration of ustekinumab (Stelara, Janssen), should prompt clinicians to reconsider where the drug sits in the treatment algorithm, said Ellen Scherl, MD, the founding director of the Jill Roberts Center for Inflammatory Bowel Disease and